SCHEDULE 13G: Soleus Capital Group Discloses 5.0% Passive Stake in Praxis Precision Medicines

Soleus Capital Master Fund, L.P. and its affiliated entities have reported a passive 5.0% beneficial ownership stake in Praxis Precision Medicines, Inc., totaling 1,017,740 shares.

Summary

• Soleus Capital Master Fund, L.P., along with its general partner Soleus Capital, LLC, managing member Soleus Capital Group, LLC, investment manager Soleus Capital Management, L.P., and general partner Soleus GP, LLC, and individual Guy Levy, collectively reported beneficial ownership of 1,017,740 shares of common stock in Praxis Precision Medicines, Inc.
• This ownership represents 5.0% of the Issuer's outstanding common stock.
• The percentage is calculated based on 20,163,250 shares of Praxis Precision Medicines, Inc. common stock outstanding as of February 26, 2025, as reported in the Issuer's Annual Report on Form 10-K.
• All reporting persons share both voting and dispositive power over the 1,017,740 shares.
• The filing is a Schedule 13G, indicating a passive investment purpose, with the reporting persons certifying that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing (Schedule 13G) disclosing a passive ownership stake. It does not contain information that would inherently convey positive or negative sentiment about the issuer's performance or prospects, beyond the neutral fact of an institutional investment.

Positives

• A significant institutional investor, Soleus Capital Master Fund, L.P., has taken a 5.0% stake in Praxis Precision Medicines, Inc., which could be viewed as a vote of confidence in the company's long-term prospects.

Future Outlook

The document is a Schedule 13G filing, which is a disclosure of passive beneficial ownership and does not contain any forward-looking statements or guidance regarding the issuer's future operations or financial performance.

Management Comments

• The reporting persons, including Guy Levy, disclaim beneficial ownership of the shares held by Soleus Capital Master Fund, L.P. other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.

Industry Context

This filing indicates a new significant passive investment in Praxis Precision Medicines, Inc. by Soleus Capital, a firm that invests across various sectors. While the filing itself does not provide industry-specific analysis, a 5% stake by an institutional investor can signal perceived value within the biotechnology or pharmaceutical sector, depending on Praxis's specific focus.

Comparison to Industry Standards

• This Schedule 13G filing is a standard regulatory disclosure for reporting a passive beneficial ownership stake exceeding 5% in a publicly traded company. It does not contain information that allows for a direct comparison of Praxis Precision Medicines, Inc.'s performance or metrics against industry benchmarks or specific comparable companies or projects.

Stakeholder Impact

• Shareholders: Existing shareholders may view the entry of a new 5% institutional investor as a positive signal, potentially increasing confidence in the stock.
• Management: Management of Praxis Precision Medicines, Inc. will be aware of this new significant passive shareholder, though it does not imply immediate operational changes or activist pressure.

Key Dates

Keywords

Praxis Precision Medicines, Soleus Capital, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Passive Stake, SEC Filing, Biotechnology, Pharmaceuticals